image credits: depositphoto
Frost & Sullivan’s recent analysis, Outlook of India’s Healthcare Industry, 2020, finds that this industry is estimated to reach $193.83 billion in 2020 from $233.14 billion in 2019, primarily due to disruptions caused by COVID-19 and subsequent lockdowns in India. Though this industry registered double-digit growth during 2015-2019, revenue is expected to witness a downturn during Q2 and Q3 of the calendar year 2020 due to international travel restrictions and nationwide lockdown restricting business from direct walk-ins, elective cases, and B2B channels. With an estimated downturn of 30%-50% year over year (YoY) from 2020-2021, the healthcare delivery industry is expected to make a “V” shaped recovery with business as usual from 2022.
“This sunrise sector of India is primarily driven by the healthcare delivery segment followed by pharmaceutical, medical devices, and healthcare insurance industries,” said Akshay Zanjurne, Transformational Health Program Manager at Frost & Sullivan. “Additionally, increasing domestic potential and rising global demand for low-cost therapies at high quality will strongly propel the biosimilars industry, whereas an estimated treatment of 14 million patients by the end of this year through Ayushman Bharat Yojana—a part of the Indian government's National Health Policy—is expected to significantly boost the demand for medical devices.”
Zanjurne added, “Amidst rising COVID-19 uncertainty, telehealth will experience tremendous growth. Government initiatives such as the National Health Portal, online registration system, and e-Hospital are expected to increase preference and adoption of e-Healthcare models. Further, superior medical services at approximately 20% less cost than that of developed countries will attract a large number of medical tourists to India.”
This impressive boom in the Indian healthcare sector is creating tremendous growth prospects for its market participants, such as:
